173 related articles for article (PubMed ID: 38748746)
1. Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2-ERK 1/2 pathway.
Maeda K; Kuriyama N; Noguchi D; Ito T; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Murata Y; Tanemura A; Kishiwada M; Mizuno S
PLoS One; 2024; 19(5):e0292628. PubMed ID: 38748746
[TBL] [Abstract][Full Text] [Related]
2. Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury.
Noguchi D; Kuriyama N; Ito T; Fujii T; Kato H; Mizuno S; Sakurai H; Isaji S
J Surg Res; 2020 Feb; 246():568-583. PubMed ID: 31653415
[TBL] [Abstract][Full Text] [Related]
3. Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
Oe Y; Hayashi S; Fushima T; Sato E; Kisu K; Sato H; Ito S; Takahashi N
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1525-33. PubMed ID: 27283743
[TBL] [Abstract][Full Text] [Related]
4. HepaticIschemia/Reperfusion Injuryinvolves functional tryptase/PAR-2 signaling in liver sinusoidal endothelial cell population.
Song J; He Z; Yang M; Yu T; Wang X; Liu B; Li J
Int Immunopharmacol; 2021 Nov; 100():108052. PubMed ID: 34454294
[TBL] [Abstract][Full Text] [Related]
5. Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in mice.
Teoh NC; Ito Y; Field J; Bethea NW; Amr D; McCuskey MK; McCuskey RS; Farrell GC; Allison AC
Gastroenterology; 2007 Aug; 133(2):632-46. PubMed ID: 17681182
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Dabigatran Treatment on Sinusoidal Protection Against Hepatic Ischemia/Reperfusion Injury in Mice.
Noguchi D; Kuriyama N; Hibi T; Maeda K; Shinkai T; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Kishiwada M; Sakurai H; Mizuno S
Liver Transpl; 2021 Feb; 27(3):363-384. PubMed ID: 33108682
[TBL] [Abstract][Full Text] [Related]
7. Alpinetin protects against hepatic ischemia/reperfusion injury in mice by inhibiting the NF-κB/MAPK signaling pathways.
Pan J; Chen S; Guo W; Cao S; Shi X; Zhang J; Zhang H; Zhang S
Int Immunopharmacol; 2021 Jun; 95():107527. PubMed ID: 33743314
[TBL] [Abstract][Full Text] [Related]
8. Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial-mesenchymal transition and inflammatory response.
Fang L; Ohashi K; Ogawa H; Otaka N; Kawanishi H; Takikawa T; Ozaki Y; Takahara K; Tatsumi M; Takefuji M; Murohara T; Ouchi N
Physiol Rep; 2022 Mar; 10(5):e15218. PubMed ID: 35262272
[TBL] [Abstract][Full Text] [Related]
9. Cellular communication network factor 1 (CCN1) knockdown exerts a protective effect for hepatic ischemia/reperfusion injury by deactivating the MEK/ERK pathway.
Liu H; Li J; Jiang C; Yuan T; Ma H
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101737. PubMed ID: 34144219
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats.
Morishima Y; Shibutani T; Noguchi K; Ito Y; Honda Y
J Thromb Thrombolysis; 2021 Jul; 52(1):9-17. PubMed ID: 33534029
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity.
Narita Y; Hamamura K; Kashiyama M; Utsumi S; Kakizoe Y; Kondo Y; Ishitsuka Y; Jono H; Irie T; Mukoyama M; Saito H; Kadowaki D; Hirata S; Kitamura K
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450643
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis.
Horinouchi Y; Ikeda Y; Fukushima K; Imanishi M; Hamano H; Izawa-Ishizawa Y; Zamami Y; Takechi K; Miyamoto L; Fujino H; Ishizawa K; Tsuchiya K; Tamaki T
Sci Rep; 2018 Jul; 8(1):10858. PubMed ID: 30022146
[TBL] [Abstract][Full Text] [Related]
14. TGR5 Attenuated Liver Ischemia-Reperfusion Injury by Activating the Keap1-Nrf2 Signaling Pathway in Mice.
Zhuang L; Ding W; Zhang Q; Ding W; Xu X; Yu X; Xi D
Inflammation; 2021 Jun; 44(3):859-872. PubMed ID: 33169298
[TBL] [Abstract][Full Text] [Related]
15. Activated clotting factor X mediates mitochondrial alterations and inflammatory responses via protease-activated receptor signaling in alveolar epithelial cells.
Bukowska A; Schild L; Bornfleth P; Peter D; Wiese-Rischke C; Gardemann A; Isermann B; Walles T; Goette A
Eur J Pharmacol; 2020 Feb; 869():172875. PubMed ID: 31877279
[TBL] [Abstract][Full Text] [Related]
16. Role of miR-148a in Mitigating Hepatic Ischemia-Reperfusion Injury by Repressing the TLR4 Signaling Pathway via Targeting CaMKIIα in Vivo and in Vitro.
Zheng D; Li Z; Wei X; Liu R; Shen A; He D; Tang C; Wu Z
Cell Physiol Biochem; 2018; 49(5):2060-2072. PubMed ID: 30244246
[TBL] [Abstract][Full Text] [Related]
17. Microparticles mediate hepatic ischemia-reperfusion injury and are the targets of Diannexin (ASP8597).
Teoh NC; Ajamieh H; Wong HJ; Croft K; Mori T; Allison AC; Farrell GC
PLoS One; 2014; 9(9):e104376. PubMed ID: 25222287
[TBL] [Abstract][Full Text] [Related]
18. Sirtuin 1 Stimulation Attenuates Ischemic Liver Injury and Enhances Mitochondrial Recovery and Autophagy.
Khader A; Yang WL; Godwin A; Prince JM; Nicastro JM; Coppa GF; Wang P
Crit Care Med; 2016 Aug; 44(8):e651-63. PubMed ID: 26963320
[TBL] [Abstract][Full Text] [Related]
19. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
[TBL] [Abstract][Full Text] [Related]
20. Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia.
Imano H; Kato R; Tanikawa S; Yoshimura F; Nomura A; Ijiri Y; Yamaguchi T; Izumi Y; Yoshiyama M; Hayashi T
J Pharmacol Sci; 2018 Jul; 137(3):274-282. PubMed ID: 30055890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
